Ascendis Pharma A (ASND) Net Income towards Common Stockholders (2014 - 2026)

Ascendis Pharma A has reported Net Income towards Common Stockholders for 13 years, with the latest figure at $740.4 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 843.24% year-over-year to $740.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $673.2 million (up 682.67% YoY) and the FY2025 annual result came in at -$269.6 million, up 33.28% from the prior year.
• Net Income towards Common Stockholders advanced to $740.4 million in Q1 2026 per ASND's latest filing, from -$39.6 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $740.4 million in Q1 2026 and troughed at -$211.6 million in Q4 2022.
• A 5-year average of $63.6 million and a median of $87.6 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders plunged 282.13% in 2022, then soared 843.24% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at -$211.6 million in 2022, then jumped by 55.07% to -$95.1 million in 2023, then surged by 56.77% to -$41.1 million in 2024, then grew by 3.58% to -$39.6 million in 2025, then surged by 1967.84% to $740.4 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $740.4 million, -$39.6 million, and -$73.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.